Pioneering Science
- Vaccines
- molecular-level understanding of immune responses and antigen manufactured synthetically.
- Universal Flu
- HIV
- Hep B and C
- Rotavirus
- Mosquito Disease Vaccine
- synthetically-manufactured elements of saliva protecting against mosquito-transported diseases.
- Mosquito borne disease
- Persistent Cough
- inhibition of vagus nerve stimulation in airways to treat cough.
- Persistent Cough
- Pain/Inflammation
- adjuvant-enhanced small molecules enticing increased uptake of drug by immune cells to treat inflammatory driven pain diseases and for the treatment of pandemic flu.
- Cholesterol Management
- adjuvant-enhanced small molecule that is capable of lowering LDL and Tri-Glycerides and increasing HDL.
- Tolerance
- adjuvant-enhanced small molecule that transforms the immunoreactive cells into regulatory cells to treat transplantation rejection and stem cell replacement for Type I diabetes treatment.
-
- SLE
- hormonal treatment for Lupus disease.
-
- Anti-Microbrial
- non-alcohol based safe treatment for bacterial, viral and fungal infections.
- Cancer
- small-molecule conjugate selectively targeting over-expressed cancer receptors to treat breast cancer.
- Breast Cancer
and adjuvant-enhanced small molecule for the treatment of hormone refractory prostate cancer.
Commercially Delivered
- Science
- no idea-loyalty; each idea rigorously analysed and discarded if currently non-viable.
- Experiments
- designed to determine if science and drugs actually work and discard at earliest possible stage before significant costs and time incurred.
- Manufacturing
- scale-up, GMP and analytics undertaken early to avoid late stage delays and disappointments.
- Regulatory
- trial designs ensure low-cost, early safety and efficacy data. Detailed knowledge of regulatory framework to achieve most truncated route to market.
- Positioning
- focus on products with first-in-class/best-in-class potential and in major disease areas.
- Protection
- implementation of proprietary market-protection strategies from the earliest stages of drug development.
- Fast to Market Products
- SEEK is developing differentiating low-cost small molecule drugs with short times-to-market in order to increase treatment availability for much larger patient populations. These products will be commercialised through SEEK’s infirst+ HEALTHCARE division.
- Collaborations
- SEEK works with other companies on the commercialisation of its products. In May 2012 SEEK signed a licensing agreement with Pernix Therapeutics Holdings, for the US marketing rights to BC1036. Under the agreement, Pernix will be responsible for the development and launch of the products in areas of cough, cold, sinus and allergy in North America. SEEK will have the rights to commercialise the products in the rest of the world.